Thursday, May 18, 2017 1:10:37 AM
Once on this page, locate picture of the RSV F Protein. Under this picture is year 2014. ( Sorry for the wild goose chase!) Note text which explains the end of Maternal Phase 2 results.
Many of you already know all about this. But many are new and searching for readily available, evidenced DD. (Note: NVAX employs different kinds of adjuvants; different, specific adjuvants, are used successfully, to best "boost " different vaccines, during or beyond trials. )
The maternal RSV trial 3 is based on the successes of trial 2, in which vaccine F was given to women of child bearing years; the vaccine F was given in a single dose, paired with the specific adjuvant, aluminum phosphate . This combination resulted in what is paraphrased here: Highest immune response observed with THIS combination; high levels of antibodies within 14 days post immunization, persisting 91 following days. (From that point, you can move on the Novavax site to the phase 3 maternal trial, involving pregnant women, and to the elderly trial).
If you want more, current DD, with well evidenced info/ research, Seeking Alpha has put out a very comprehensive review of trials and last weeks conference call, including links to relevant science journals. No reason to be persuaded by premature or inaccurate opinions and surmising from "professional " analysts, possibly setting up the recent share price drop, and short attack. At the bottom of text # 4129 is the information re: the location of the Seeking Alpha report. You decide. Just type in 4129 in the white box above. All stated here is IMO.
Recent NVAX News
- Novavax Names Dr. Ruxandra Draghia-Akli as New Executive Vice President and Head of Research & Development • PR Newswire (US) • 09/25/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 09/18/2024 08:08:16 PM
- Novavax 2024-2025 Formula COVID-19 Vaccine Available at Major Pharmacies Across the U.S. • PR Newswire (US) • 09/13/2024 01:25:00 PM
- Novavax to Participate in Upcoming September Conferences • PR Newswire (US) • 09/04/2024 01:25:00 PM
- Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. • PR Newswire (US) • 08/30/2024 08:19:00 PM
- Novavax 2024-2025 Formula COVID-19 Vaccine Now Authorized and Recommended for Use in the U.S. • PR Newswire (US) • 08/30/2024 07:46:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/21/2024 08:47:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/20/2024 09:06:20 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:15:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 12:04:56 PM
- Novavax Reports Second Quarter 2024 Financial Results and Operational Highlights • PR Newswire (US) • 08/08/2024 12:02:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 11:37:07 AM
- U.S. Index Futures Drop, Signaling Ongoing Market Volatility; Oil Prices Stall • IH Market News • 08/08/2024 09:55:44 AM
- Novavax to Host Conference Call to Discuss Second Quarter 2024 Financial Results and Operational Highlights on August 8, 2024 • PR Newswire (US) • 08/01/2024 01:25:00 PM
- ASML Rises 7% on Export Waiver; Intel Plans Layoffs, HSBC $3B Buyback Announced, and More • IH Market News • 07/31/2024 09:55:50 AM
- Novavax Submits Application to Health Canada for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine • PR Newswire (Canada) • 07/02/2024 12:30:00 PM
- Novavax Submits Application to European Medicines Agency for Updated Protein-based 2024-2025 Formula COVID-19 Vaccine • PR Newswire (US) • 06/24/2024 01:18:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/18/2024 08:09:02 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 06/17/2024 08:13:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:14:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:11:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:10:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:07:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:06:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 08:05:38 PM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM